Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

VPAC1 (IHC-grade), VIP Receptor 1 Antibody

Citations
$ 375.00 *

Prices plus VAT plus shipping costs

Ready to ship today,
Delivery time appr. 5-8 days

  • 7TM0371N-IC
  • 100 µl
  • Rabbit
The VPAC1 antibody is directed against the distal end of the carboxyl-terminal tail of human VIP... more

The VPAC1 antibody is directed against the distal end of the carboxyl-terminal tail of human VIP Receptor 1. It can be used to detect total VPAC1 receptors in Western blots independent of phosphorylation. The VPAC1 antibody can also be used to isolate and enrich VPAC1 receptors from cell and tissue lysates. It also detects VPAC1 in cultured cells and tissue sections by immunohistochemistry.

  Alternative Names VPAC1, VIP Receptor 1, Vasoactive Intestinal Peptide... more

 

Alternative Names VPAC1, VIP Receptor 1, Vasoactive Intestinal Peptide Receptor 1
IUPHAR Target ID  371
UniProt ID  P32241
Western Blot (WB)  1:1000
Immunocytochemistry (ICC) 1:200
Immunohistochemistry (IHC) 1:100
Species Reactivity   Human
Host / Isotype Rabbit / IgG
Class Polyclonal
Immunogen A synthetic peptide with sequence TRVSPGARRSSSFQAEVSLV corresponds to amino acids 438-457 of human VPAC1
Form  Liquid
Purification Antigen affinity chromatography
Storage buffer Dulbecco's PBS, pH 7.4, with 150 mM NaCl, 0.02% sodium azide
Storage conditions short-term 4°C, long-term -20°C
Figure 1. Immunohistochemical identification of VIP Receptor 1 in small intestine. Sections... more

Figure 1. Immunohistochemical identification of VIP Receptor 1 in small intestine. Sections were dewaxed, microwaved in citric acid, and incubated with anti-VPAC1 (VIP Receptor 1) antibody (7TM0371N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, VPAC1 receptors were uniformly detected at plasma membrane of eptihelial cells.

Figure 2. Immunohistochemical identification of VIP Receptor 1 in small intestine. Sections were dewaxed, microwaved in citric acid, and incubated with anti-VPAC1 (VIP Receptor 1) antibody (7TM0371N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, VPAC1 receptor staining is absent in muscosa but located in basal portion of the crypts.

Figure 3. Immunohistochemical identification of VIP Receptor 1 in enteric ganglia. Sections were dewaxed, microwaved in citric acid, and incubated with anti-VPAC1 (VIP Receptor 1) antibody (7TM0371N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, VPAC1 receptors were uniformly detected in nearly all cells of enteric ganglia.

Figure 4. Immunohistochemical identification of VIP Receptor 1 in neuroendocrine tumor. Sections were dewaxed, microwaved in citric acid, and incubated with anti-VPAC1 (VIP Receptor 1) antibody (7TM0371N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, VPAC1 receptors were detected in a population of distinct cells in neuroendocrine tumor.

Figure 5. Immunohistochemical identification of VIP Receptor 1 in breast carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-VPAC1 (VIP Receptor 1) antibody (7TM0371N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, VPAC1 receptors were detected in a population of distinct cells in breast carcinoma.


Figure 6. Validation of the VIP receptor 1 in transfected HEK293 cells. Native HEK293 cells (MOCK) or HEK293 cells stably expressing the VIP Receptor 1 (VPAC1) were lysed and immunoblotted with the anti-VPAC1 antibody (7TM0371N-IC) at a dilution of 1:1000.


Figure 7. Immunocytochemical identification of VIP Receptor 1 in HEK293 cells. Native HEK293 cells (MOCK) or HEK293 cells stably expressing the VIP Receptor 1 (VPAC1) were immunocytochemically stained with anti-VPAC1 (VIP Receptor 1) antibody (7TM0371N-IC) at a dilution of 1:200. Note, VPAC1 receptors were confined to the plasma membrane in transfected cells.


Read, write and discuss reviews... more
Customer evaluation for "VPAC1 (IHC-grade), VIP Receptor 1 Antibody"
Write an evaluation
Evaluations will be activated after verification.

The fields marked with * are required.

Recently viewed